USCA RIA’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
$5.14M Sell
76,998
-15,719
-17% -$1.02M 0.31% 97
2021
Q1
$5.85M Sell
92,717
-14,297
-13% -$890K 0.38% 71
2020
Q4
$6.64M Sell
107,014
-6,114
-5% -$376K 0.47% 46
2020
Q3
$6.82M Sell
113,128
-19,590
-15% -$1.18M 0.53% 39
2020
Q2
$7.8M Buy
132,718
+12,789
+11% +$765K 0.69% 28
2020
Q1
$6.68M Sell
119,929
-3,768
-3% -$230K 0.78% 27
2019
Q4
$7.94M Buy
123,697
+15,915
+15% +$911K 0.71% 30
2019
Q3
$5.47M Buy
107,782
+4,120
+4% +$194K 0.54% 57
2019
Q2
$4.7M Sell
103,662
-57,618
-36% -$2.68M 0.48% 61
2019
Q1
$7.7M Buy
161,280
+134,171
+495% +$6.68M 0.84% 28
2018
Q4
$1.41M Sell
27,109
-17,219
-39% -$925K 0.19% 141
2018
Q3
$2.75M Sell
44,328
-1,193
-3% -$70.8K 0.28% 116
2018
Q2
$2.52M Sell
45,521
-3,735
-8% -$202K 0.27% 119
2018
Q1
$3.12M Sell
49,256
-10,170
-17% -$654K 0.34% 82
2017
Q4
$3.64M Sell
59,426
-56,969
-49% -$3.56M 0.4% 75
2017
Q3
$6.49M Hold
116,395
0.84% 25
2017
Q2
$6.49M Buy
116,395
+66,872
+135% +$3.64M 0.83% 25
2017
Q1
$2.69M Buy
49,523
+8,814
+22% +$483K 0.39% 70
2016
Q4
$2.38M Buy
40,709
+3,297
+9% +$180K 0.37% 76
2016
Q3
$2.02M Buy
37,412
+18,700
+100% +$1.2M 0.33% 89
2016
Q2
$1.38M Sell
18,712
-1,192
-6% -$84.2K 0.23% 129
2016
Q1
$1.27M Buy
19,904
+486
+3% +$30.6K 0.23% 129
2015
Q4
$1.34M Sell
19,418
-174
-0.9% -$11.5K 0.29% 107
2015
Q3
$1.16M Sell
19,592
-137
-0.7% -$8.69K 0.29% 98
2015
Q2
$1.31M Buy
19,729
+1,178
+6% +$77.6K 0.35% 77
2015
Q1
$1.2M Buy
18,551
+3,241
+21% +$203K 0.32% 84
2014
Q4
$904K Sell
15,310
-1,015
-6% -$57.2K 0.25% 106
2014
Q3
$835K Buy
16,325
+335
+2% +$16.7K 0.25% 116
2014
Q2
$776K Buy
15,990
+1
+0% +$49 0.26% 113
2014
Q1
$831K Sell
15,989
-314
-2% -$16.7K 0.3% 108
2013
Q4
$867K Sell
16,303
-6,176
-27% -$315K 0.35% 90
2013
Q3
$1.04M Sell
22,479
-552
-2% -$24.2K 0.47% 64
2013
Q2
$1.03M Buy
+23,031
New +$1,000K 0.52% 48

Other funds holding BMY

USCA RIA's BMY Position: Q2 2021 in Review

USCA RIA reduced its Bristol-Myers Squibb (BMY) stake by 17% in Q2 2021, selling an estimated $1.02M and leaving 76,998 shares worth $5.14M. The position accounts for 0.31% of the portfolio, ranked #97.

USCA RIA first reported a position in BMY in Q2 2013 and has held it in 33 quarters since. The position peaked at $7.94M in Q4 2019. 2,369 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

  • USCA RIA held 76,998 shares of Bristol-Myers Squibb worth $5.14M as of Q2 2021.
  • USCA RIA sold 15,719 Bristol-Myers Squibb shares in Q2 2021, an estimated $1.02M.
  • Bristol-Myers Squibb made up 0.31% of USCA RIA's portfolio in Q2 2021, its #97 holding.
  • USCA RIA first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 33 quarters since.
  • USCA RIA's Bristol-Myers Squibb position peaked at $7.94M in Q4 2019.
  • 2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.